LLY vs VOR

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Vor Biopharma continues to present a high-risk, high-reward opportunity, demonstrating 10x growth potential within 3-5 years if key clinical milestones are met. A significant strategic pivot is evident since the last analysis, with the company now primarily focused on telitacicept for autoimmune diseases (gMG and Sjögren’s disease) via late-stage Phase 3 clinical trials, replacing its prior focus ...